Mer­ck KGaA snatch­es up Gene­va biotech as re­pur­posed chemother­a­py mis­sion strikes a 'Chord'

About a year af­ter Gene­va-based Chord Ther­a­peu­tics emerged from stealth to see if it could re­pur­pose an old chemother­a­py agent for rare dis­eases, Mer­ck KGaA is swoop­ing in with a buy­out.

While the com­pa­nies are keep­ing mum about the fi­nan­cial terms of the deal, Mer­ck KGaA is adding Chord’s lead can­di­date to its neu­rol­o­gy pipeline — a small mol­e­cule oral ver­sion of the chemother­a­py drug cladrib­ine dubbed CRD1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER